News

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing…
Read More...

Johnson & Johnson announced it is updating its brand and uniting both its two business segments under the Johnson & Johnson brand name in the UK. The announcement marks the…
Read More...

Bayer and the German-based life science company, Evotec, announced that they have updated the focus of their strategic collaboration to developing innovative precision treatments for…
Read More...

Enlaza Therapeutics, the first covalent biologic platform company, announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary…
Read More...

Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration has approved INGREZZA SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA…
Read More...

Merck, a leading science and technology company, is investing more than € 300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research…
Read More...

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of…
Read More...

Incyte and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders,…
Read More...

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Ochre Bio, a pioneer in chronic liver disease medicine development, announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for…
Read More...

TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA…
Read More...

Evotec SE and Variant Bio, Inc. announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Fibrosis is characterised by marked and…
Read More...

Vertex Pharmaceuticals Incorporated announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and…
Read More...

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, exits from stealth following a $10m seed financing round. Outrun's platform has enabled it…
Read More...

IGM Biosciences, Inc. announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on…
Read More...